BHOCBiological Hemoglobin Oxygen Carrier
Partners & research collaborators

Make one question
testable together.

We are looking for teams that can define an organ-specific protocol, run the measurements and evaluate the result.

Collaboration areas

A defined role for each team.

01 / CLINICAL & PERFUSION

Transplant and organ teams

Define an organ, donor context, comparator, perfusion conditions and function endpoints. Evaluate kidney, liver, heart and lung on their own terms.

02 / METABOLISM & PRODUCT

Measurement and formulation

Characterize oxygen affinity, temperature response, oxidation, stability and tissue-level readouts before testing any clinical promise.

03 / SPECIALIST PATHWAYS

Xenografts and organ engineering

Study possible compatibility with gene-edited donors, ex-vivo interventions or engineered grafts in separate studies. BHOC itself is not a genetic editing method.

04 / DEVELOPMENT

Manufacturing and regulation

Plan quality systems, safety work, manufacturing capacity and regulatory discussions appropriate to the product and setting.

05 / Independent Advocacy

A voice free to disagree.

Independent patients, care partners, clinicians, ethicists and scientists can challenge benefit, safety and access. What result would make us change course? Their scrutiny helps BHOC correct its work, makes evidence clearer to society and keeps patient needs in the decision.

Nature is the engineer.
We are still learning.

“All life needs oxygen”* expresses why we focus on oxygen-dependent human cells and transplanted organs. Nature has shaped hemoglobin-based oxygen binding over hundreds of millions of years.

We learn from its reversible binding. For BHOC, an “unlimited source of material”** means starting material independent of human blood donation and available through scalable supply chains worldwide. For a defined BHOC product, oxygen release as local pressure changes, behavior during cooling and rewarming, and any role of nitric oxide in vascular-flow regulation*** must be measured. Independent evidence should correct both our understanding and the technology.

Jeff Parke, founder of Cold Ischemia Foundation
Portrait source ↗
First independent perspective

Jeff Parke

Founder and Executive Director, Cold Ischemia Foundation. In his own account, he describes roughly two decades on dialysis and three kidney transplants. He also brings experience in clinical research.

“That evidence is the only honest route to what patients actually need: kidneys that last, not just kidneys that arrive.”

His foundation explains BHOC as an emerging research direction and asks for product-specific kidney-perfusion evidence. His coverage is independent and does not constitute an endorsement or clinical recommendation.

Propose a specific test.

Tell us the organ, setting, methods and measurements your team can contribute.

Discuss an organ-perfusion study →